Wall Street analysts forecast that MAXIMUS, Inc. (NYSE:MMS) will report $617.67 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for MAXIMUS’s earnings, with the highest sales estimate coming in at $622.79 million and the lowest estimate coming in at $611.80 million. MAXIMUS posted sales of $622.05 million during the same quarter last year, which would indicate a negative year over year growth rate of 0.7%. The firm is expected to report its next quarterly earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that MAXIMUS will report full-year sales of $617.67 million for the current year, with estimates ranging from $2.48 billion to $2.50 billion. For the next financial year, analysts expect that the firm will report sales of $2.61 billion per share, with estimates ranging from $2.59 billion to $2.63 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for MAXIMUS.

How to Become a New Pot Stock Millionaire

MAXIMUS (NYSE:MMS) last issued its quarterly earnings results on Thursday, February 8th. The health services provider reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.01. MAXIMUS had a return on equity of 22.93% and a net margin of 8.99%. The firm had revenue of $623.10 million for the quarter, compared to analysts’ expectations of $624.36 million. During the same quarter in the prior year, the firm earned $0.71 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year.

A number of research analysts have recently commented on the company. Maxim Group reaffirmed a “hold” rating and set a $69.00 price target (up previously from $66.00) on shares of MAXIMUS in a research report on Thursday, February 8th. Canaccord Genuity reaffirmed a “buy” rating on shares of MAXIMUS in a research report on Wednesday, December 27th. Finally, Zacks Investment Research raised MAXIMUS from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $66.60.

In related news, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $67.89, for a total transaction of $2,036,700.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $71.73, for a total value of $71,730.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,600 shares of company stock worth $3,014,830. 3.10% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Amundi Pioneer Asset Management Inc. bought a new stake in shares of MAXIMUS during the 4th quarter valued at $163,000. Steward Partners Investment Advisory LLC bought a new stake in shares of MAXIMUS during the 4th quarter valued at $169,000. Capital One National Association bought a new stake in shares of MAXIMUS during the 4th quarter valued at $213,000. Zeke Capital Advisors LLC bought a new stake in shares of MAXIMUS during the 4th quarter valued at $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of MAXIMUS by 51.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,581 shares of the health services provider’s stock valued at $256,000 after purchasing an additional 1,214 shares during the period. Institutional investors own 96.72% of the company’s stock.

Shares of MAXIMUS (NYSE MMS) traded up $0.27 during midday trading on Wednesday, hitting $68.11. The stock had a trading volume of 773,495 shares, compared to its average volume of 415,435. MAXIMUS has a 1 year low of $57.12 and a 1 year high of $72.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57. The stock has a market cap of $4,424.75, a PE ratio of 20.27, a PEG ratio of 2.26 and a beta of 1.18.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Thursday, February 15th were paid a dividend of $0.045 per share. The ex-dividend date was Wednesday, February 14th. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.26%. MAXIMUS’s payout ratio is 5.36%.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect MAXIMUS, Inc. (MMS) Will Post Quarterly Sales of $617.67 Million” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/zacks-brokerages-expect-maximus-inc-mms-will-post-quarterly-sales-of-617-67-million/1940929.html.


MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on MAXIMUS (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.